Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?
News NHS starts first national rollout of Blenrep for myeloma England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.
News BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
News FDA clears Nuvation's first product Ibtrozi, for lung cancer Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
News BMS' radiopharma unit builds with $1.35bn Philochem deal Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
News AZ claims EU approval for new Calquence regimens in CLL AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
